Literature DB >> 22611241

Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma.

Dalya R Soond1, Fabien Garçon, Daniel T Patton, Julia Rolf, Martin Turner, Cheryl Scudamore, Oliver A Garden, Klaus Okkenhaug.   

Abstract

PTEN, one of the most commonly mutated or lost tumor suppressors in human cancers, antagonizes signaling by the PI3K pathway. Mice with thymocyte-specific deletion of Pten rapidly develop peripheral lymphomas and autoimmunity, which may be caused by failed negative selection of thymocytes or from dysregulation of postthymic T cells. We induced conditional deletion of Pten from CD4 Th cells using a Cre knocked into the Tnfrsf4 (OX40) locus to generate OX40(Cre)Pten(f) mice. Pten-deficient Th cells proliferated more and produced greater concentrations of cytokines. The OX40(Cre)Pten(f) mice had a general increase in the number of lymphocytes in the lymph nodes, but not in the spleen. When transferred into wild-type (WT) mice, Pten-deficient Th cells enhanced anti-Listeria responses and the clearance of tumors under conditions in which WT T cells had no effect. Moreover, inflammatory responses were exaggerated and resolved later in OX40(Cre)Pten(f) mice than in WT mice. However, in contrast with models of thymocyte-specific Pten deletion, lymphomas and autoimmunity were not observed, even in older OX40(Cre)Pten(f) mice. Hence loss of Pten enhances Th cell function without obvious deleterious effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22611241      PMCID: PMC3378038          DOI: 10.4049/jimmunol.1102116

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models.

Authors:  E Astoul; C Edmunds; D A Cantrell; S G Ward
Journal:  Trends Immunol       Date:  2001-09       Impact factor: 16.687

2.  The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites.

Authors:  Molly S Thomas; Jason S Mitchell; Christopher C DeNucci; Amanda L Martin; Yoji Shimizu
Journal:  J Leukoc Biol       Date:  2008-06-03       Impact factor: 4.962

3.  Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements.

Authors:  M J Barnden; J Allison; W R Heath; F R Carbone
Journal:  Immunol Cell Biol       Date:  1998-02       Impact factor: 5.126

Review 4.  Origins of CD4(+) effector and central memory T cells.

Authors:  Marion Pepper; Marc K Jenkins
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

Review 5.  Follicular helper CD4 T cells (TFH).

Authors:  Shane Crotty
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

6.  PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus.

Authors:  Domingo F Barber; Almira Bartolomé; Carmen Hernandez; Juana M Flores; Clara Redondo; Cristina Fernandez-Arias; Montserrat Camps; Thomas Rückle; Matthias K Schwarz; Santiago Rodríguez; Carlos Martinez-A; Dimitrios Balomenos; Christian Rommel; Ana C Carrera
Journal:  Nat Med       Date:  2005-08-28       Impact factor: 53.440

7.  Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction.

Authors:  Julia Rolf; Sarah E Bell; Dorottya Kovesdi; Michelle L Janas; Dalya R Soond; Louise M C Webb; Sara Santinelli; Ted Saunders; Barbara Hebeis; Nigel Killeen; Klaus Okkenhaug; Martin Turner
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

8.  T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus.

Authors:  T J Hagenbeek; H Spits
Journal:  Leukemia       Date:  2007-11-29       Impact factor: 11.528

9.  Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase.

Authors:  Amanda L Martin; Matthew D Schwartz; Stephen C Jameson; Yoji Shimizu
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

10.  Defective CD8 T cell memory following acute infection without CD4 T cell help.

Authors:  Joseph C Sun; Michael J Bevan
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

View more
  23 in total

Review 1.  The functions of tumor suppressor PTEN in innate and adaptive immunity.

Authors:  Lang Chen; Deyin Guo
Journal:  Cell Mol Immunol       Date:  2017-06-26       Impact factor: 11.530

2.  MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles.

Authors:  W He; C Wang; R Mu; P Liang; Z Huang; J Zhang; L Dong
Journal:  Oncogene       Date:  2017-03-27       Impact factor: 9.867

3.  PTEN at the interface of immune tolerance and tumor suppression.

Authors:  Andrew Brandmaier; Sheng-Qi Hou; Sandra Demaria; Silvia C Formenti; Wen H Shen
Journal:  Front Biol (Beijing)       Date:  2017-03-04

4.  PTEN is a negative regulator of NK cell cytolytic function.

Authors:  Edward L Briercheck; Rossana Trotta; Li Chen; Alex S Hartlage; Jordan P Cole; Tyler D Cole; Charlene Mao; Pinaki P Banerjee; Hsiang-Ting Hsu; Emily M Mace; David Ciarlariello; Bethany L Mundy-Bosse; Isabel Garcia-Cao; Steven D Scoville; Lianbo Yu; Robert Pilarski; William E Carson; Gustavo Leone; Pier Paolo Pandolfi; Jianhua Yu; Jordan S Orange; Michael A Caligiuri
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

Review 5.  Oncogenic PTEN functions and models in T-cell malignancies.

Authors:  M Tesio; A Trinquand; E Macintyre; V Asnafi
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

6.  Lipid phosphatases identified by screening a mouse phosphatase shRNA library regulate T-cell differentiation and protein kinase B AKT signaling.

Authors:  Liying Guo; Craig Martens; Daniel Bruno; Stephen F Porcella; Hidehiro Yamane; Stephane M Caucheteux; Jinfang Zhu; William E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

Review 7.  Signaling by the phosphoinositide 3-kinase family in immune cells.

Authors:  Klaus Okkenhaug
Journal:  Annu Rev Immunol       Date:  2013-01-16       Impact factor: 28.527

Review 8.  Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.

Authors:  Klaus Okkenhaug; Mariona Graupera; Bart Vanhaesebroeck
Journal:  Cancer Discov       Date:  2016-09-21       Impact factor: 39.397

Review 9.  PI3Kδ and primary immunodeficiencies.

Authors:  Carrie L Lucas; Anita Chandra; Sergey Nejentsev; Alison M Condliffe; Klaus Okkenhaug
Journal:  Nat Rev Immunol       Date:  2016-09-12       Impact factor: 53.106

10.  All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells.

Authors:  Christopher J Gamper; Jonathan D Powell
Journal:  Front Immunol       Date:  2012-10-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.